Moleculin Biotech (NASDAQ: MBRX) has announced an Australian patent covering the preparation of preliposomal Annamycin lyophilizate, strengthening its intellectual property protection for the formulation technology.
According to Moleculin, this patent is part of Moleculin’s broader global intellectual property portfolio covering complementary technologies associated with Annamycin, the company’s investigational anthracycline.
In a statement, Walter Klemp, chairman and CEO of Moleculin, commented, “Securing this patent in Australia represents another step in our efforts to build a strong international intellectual property position around Annamycin. Our formulation technology is an important component of Annamycin’s development, and protecting this technology across international markets supports our broader intellectual property strategy.”
